Search

Weintraub, D, RA Hauser, V Abler, E Eyal, and RE Eliaz. 2016. “Rasagiline for Mild Cognitive Impairment in Parkinson’s Disease: A Placebo-Controlled Trial. Mov Disord 2016;31:709-14.”. Mov Disord.

Investigators, Huntington Study Group PHAROS. 2016. “Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol 2016;73:102-110.”. JAMA Neurol.

Stegemoller, EL, P Schmidt, , and National Parkinson Foundation Quality Improvement Initiative Investigators. 2015. “How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease? Arch Phys Med Rehabil 2015;96:1728-32.”. Arch Phys Med Rehabil.

Investigators, FS-ZONE. 2015. “Pioglitazone in Early Parkinson’s Disease: A Phase 2, Multicentre, Double-Blind, Randomised Trial. NINDS Exploratory Trials in Parkinson Disease (NET-PD). Lancet Neurol 2015;14:795-803.”. Lancet Neurol.

Nutt, JG, AD Siderowf, M Guttman, PN Schmidt, RA Hauser, and . 2014. “Mobility, Mood and Site of Care Impact Health Related Quality of Life in Parkinson’s Disease. Parkinsonism Relat Disord 2014;20:274-9.”. Parkinsonism Relat Disord.

Cicchetti, F, S Lacroix, G Cisbani, N Vallieres, M Saint-Pierre, I St-Amour, R Tolouei, J Skepper, RA Hauser, and . 2014. “Mutant Huntingtin Is Present in Neuronal Grafts in Huntington’s Disease Patients. Ann Neurol 2014;76:31-42.”. Ann Neurol.

“Hauser RA. How to Dose Carbidopa and Levodopa Extended Release Capsules (Rytary). Clinical Medicine Journal 2015;1:34-7.”. 2015. Clinical Medicine Journal.

Pahwa, R, CM Tanner, RA Hauser, K Sethi, S Isaacson, D Truong, L Struck, et al. 2015. “Amantadine Extended Release for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASED Study). Mov Disord 2015;30:788-95.”. Mov Disord.

O’Brien, CF, R Jimenez, RA Hauser, SA Factor, J Burke, D Mandri, and JC Castro-Gayol. 2015. “NBI-98854, a Selective Monoamine Transport Inhibitor for the Treatment of Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study. Mov Disord 2015;30:1681-7.”. Mov Disord.

Espay, AJ, PA LeWitt, RA Hauser, A Merola, M Masellis, and AE Lang. 2016. “Neurogenic Orthostatic Hypotension and Supine Hypertension in Parkinson’s Disease and Related Synucleinopathies: Prioritisation of Treatment Targets. Lancet Neurol 2016;15:954-66.”. Lancet Neurol.